Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: Analysis of results from the Caspofungin Empirical Therapy Study

Transplant Infectious Disease

Volumn 8, Issue 1, 2006, Pages 31-37

  De Pauw, B E ^a   Sable, C A ^b   Walsh, T J ^c   Lupinacci, R J ^b   Bourque, M R ^b   Wise, B A ^b   Nguyen, B Y ^b   DiNubile, M J ^b   Teppler, H ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Caspofungin; Endpoints; Fever; Liposomal amphotericin B; Neutropenia

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EMPIRICISM; EXPLORATORY RESEARCH; FEBRILE NEUTROPENIA; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STRATIFICATION; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PEPTIDES, CYCLIC; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33645726603     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00127.x     Document Type: Article

References (19)

1. Klastersky J. Antifungal therapy in patients with fever and neutropenia - more rational and less empirical? N Engl J Med 2004 351 1445 1447.
2. Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia salient features and comments. Clin Infect Dis 2004 39 Suppl 1 S44 S48.
3. Boogaerts M Winston DJ Bow EJ et al. Intravenous and oral itraconazole versus Intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001 135 412 422.
4. Freemantle N Calvert M Wood J Eastaugh J Griffin C. Composite outcomes in randomized trials greater precision but with greater uncertainty? JAMA 2003 289 2554 2559.
5. Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents 2004 23 105 112.
6. Walsh TJ Finberg RW Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 340 764 771.
7. Walsh TJ Pappas P Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 346 225 234.
8. Walsh TJ Teppler H Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 1391 1402.
9. Walsh TJ Pappas PG Winston D. Voriconazole for empirical antifungal therapy. N Engl J Med 2002 346 1746 1747.
10. Bodey GP Rodriguez V Chang HY Narboni Fever and infection in leukemic patients a study of 494 consecutive patients. Cancer 1978 41 1610 1622.
11. Chang JC Gross HM. Utility of naproxen in the differential diagnosis of fever of undetermined origin in patients with cancer. Am J Med 1984 76 597 603.
12. Klastersky J Paesmans M Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000 18 3038 3051.
13. Luft FC Rissing JP White A Brooks GF. Infections or neoplasm as causes of prolonged fever in cancer patients. Am J Med Sci 1976 272 65 74.
14. Pizzo PA Robichaud KJ Wesley R Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982 61 153 165.
15. Lin MT Lu HC Chen WL. Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer. Clin Infect Dis 2001 33 1621 1627.
16. Marr KA. Empirical antifungal therapy - new options, new tradeoffs. N Engl J Med 2002 346 278 280.
17. Winston DJ Hathorn JW Schuster MG Schiller GJ Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000 108 282 289.
18. Subira M Martino R Gomez L Marti JM Estany C Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol 2004 72 342 347.
19. Walsh TJ Rubin M Hathorn J et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med 1991 151 765 770.